The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), High Cholesterol, Peripheral Vascular Disease, Cardiology, Diabetes |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | January 2006 |
| End Date: | June 2008 |
| Contact: | Charles M White, PharmD |
| Email: | Cmwhite@harthosp.org |
| Phone: | 860-545-2221 |
The Use of Magnesium to Improve Hemodynamics, Cholesterol, and Glucose Control: A Substudy of AdMag
The purpose of this study is to determine if magnesium can improve blood pressure,
cholesterol, and blood sugar control in patients with implantable cardioverter
defibrillators (ICDs).
cholesterol, and blood sugar control in patients with implantable cardioverter
defibrillators (ICDs).
Magnesium is the second most abundant intracellular cation and plays a vital role in many
physiologic processes. It has been determined that patients with cardiovascular disease have
intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the
United States 64% and 77% of patients also carry the diagnosis of CAD, respectively.
Patients with CAD have risk factors that lead to the development and or propagation of
atherosclerosis. Paramount among these risk factors are hypertension, dyslipidemia, and
diabetes.
Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they
have on cholesterol, blood pressure, and blood glucose.
physiologic processes. It has been determined that patients with cardiovascular disease have
intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the
United States 64% and 77% of patients also carry the diagnosis of CAD, respectively.
Patients with CAD have risk factors that lead to the development and or propagation of
atherosclerosis. Paramount among these risk factors are hypertension, dyslipidemia, and
diabetes.
Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they
have on cholesterol, blood pressure, and blood glucose.
Inclusion Criteria:
- Newly implanted ICD or recent ICD shock (within 6 months)
Exclusion Criteria:
- Inability to swallow
- A non-cardiac disease with a survival prognosis of less than 12 months
- Hypermagnesemia
- Creatinine clearance less than 30mL/min
- Lactic acidosis or systemic acidosis syndrome
- Previous intolerance to magnesium L-lactate
We found this trial at
1
site
The Hartford Hospital Hartford Hospital is the major teaching hospital affiliated with the University of...
Click here to add this to my saved trials
